Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Clinical therapeutics - 1 Feb 2016

Swallow Elyse, Song Jinlin, Yuan Yong, Kalsekar Anupama, Kelley Caroline, Peeples Miranda, Mu Fan, Ackerman Peter, Signorovitch James

Abstract excerpt

PURPOSE: Our aim was to compare the efficacy and tolerability of daclatasvir plus sofosbuvir (DCV+SOF) versus SOF plus ribavirin (SOF+R) in patients coinfected with HIV and hepatitis C virus (HCV). METHODS: A systematic literature review of Phase III clinical trials identified 2 trials of SOF+R-PHOTON-1 (A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coinfection

Share to Imidazoles

Share to Pyrrolidines

Share to Ribavirin

Share to Sofosbuvir

Share to Valine

Source

Identifiers

PMID: 26839044
DOI: 10.1016/j.clinthera.2015.12.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.PMID 26839044Read ↗

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.Semantic proximity Read ↗

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.Semantic proximity Read ↗

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.Semantic proximity Read ↗

Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.Semantic proximity Read ↗

Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis.Semantic proximity Read ↗

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.Semantic proximity Read ↗

Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.Semantic proximity Read ↗

Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.